Details of the Drug Combinations

General Information of This Drug (ID: DM3FXPS)

• Drug Name: Liraglutide (DM3FXPS)
• Synonyms: Liraglutida; Liraglutidum; Victoza; NN 2211; NN2211; Liraglutida [INN-Spanish]; Liraglutide [USAN:INN]; Liraglutidum [INN-Latin]; NN-2211; Victoza (TN); N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide; N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide

Indication

Non-insulin dependent diabetes; ICD 11: 5A11; Status: Approved [1]; Type-2 diabetes; ICD 11: 5A11; Status: Approved [2]; Obesity; ICD 11: 5B81; Status: Phase 2 [2]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

8 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Liraglutide + Exenatide	DC0AML7	Exenatide	Diabetes	[3]
Liraglutide + Insulin-aspart	DC4P2O4	Insulin-aspart	Diabetes Mellitus, Type II	[4]
Liraglutide + Metformin	DCH1UQH	Metformin	Prediabetes	[5]
Liraglutide + Empagliflozin	DCHEELX	Empagliflozin	Diabetes Mellitus, Type 2	[6]
Liraglutide + Canagliflozin	DCIVP8Z	Canagliflozin	Type 2 Diabetes Mellitus	[7]
Liraglutide + Sitagliptin	DCQ63IQ	Sitagliptin	Diabetes	[8]
Liraglutide + Glimepiride	DCR8KQW	Glimepiride	Diabetes	[9]
Liraglutide + Phentermine	DCAJ1SH	Phentermine	Obesity	[10]

References

• [1] Liraglutide FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1133).
• [3] ClinicalTrials.gov (NCT01676116) The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy
• [4] ClinicalTrials.gov (NCT01654120) Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics
• [5] ClinicalTrials.gov (NCT01779362) RISE Adult Medication Study
• [6] ClinicalTrials.gov (NCT03993132) A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
• [7] ClinicalTrials.gov (NCT02324842) Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients
• [8] ClinicalTrials.gov (NCT02077946) A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden
• [9] ClinicalTrials.gov (NCT01511692) Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes
• [10] ClinicalTrials.gov (NCT02911818) Lifestyle Modification and Liraglutide